FORM D	UNITED STATES SECURITIES
Notice of Exempt	AND EXCHANGE COMMISSION
Offering of Securities	Washington, D.C.
1. Issuer's Ident	ity

OMB APPROVAL
OMB Number: 3235-0076
Expires: June 30, 2012
Estimated Average burden hours per response: 4.0

1

CIK (Filer ID Number)	Previous Name(s)	Vone None	Entity Type
0001404281			Corporation
Name of Issuer			C Limited Partnership
Tokai Pharmaceuticals Inc			C Limited Liability Company
Jurisdiction of Incorporation/Organization			C General Partnership
DE			C Business Trust
Year of Incorporation/Organ	ization		C Other
Over Five Years Ago			L
O Within Last Five Years (Specify Year)			
C Yet to Be Formed			

2. Principal Place of Business and Contact Information

Name of Issuer				
Tokai Pharmaceuticals Inc				
Street Address 1		Stre	et Address 2	
1 Broadway		14T	H FLOOR	
City	State/Province/Count	try	ZIP/Postal Code	Phone No. of Issuer
Cambridge	MA		02142	617-225-4305

3. Related Persons

Last Name	First Name	Middle Name
Harrison	Seth	L.
Street Address 1		Street Address 2
1 Broadway		14th Floor
City	State/Provinc	ce/Country ZIP/Postal Code
Cambridge	MA	02142
Relationship:	Executive Officer	Director Promoter
Clarification of Response (i	f Necessary)	
		
Last Name	First Name	Middle Name
Chappel	Scott	
Street Address 1		Street Address 2
1 Broadway		14th Floor
City	State/Provinc	ce/Country ZIP/Postal Code

r	
ZIP/Postal Code	
r	
1	
r	
Middle Name	
r	
]	
r	

Cambridge	MA		02142	
Relationship:	Executive Officer	Director	Promoter	
Clarification of Res	ponse (if Necessary)			

4. Industry Group

C Agriculture

- **Banking & Financial Services**
- C Commercial Banking
- C Insurance
- C Investing
- C Investment Banking C Pooled Investment Fund
- Other Banking & Financial
- C Services

C Business Services

Energy

- C Coal Mining
- C Electric Utilities
- C Energy Conservation C Environmental Services
- C Oil & Gas
- C Other Energy

Health Care

- Biotechnology
- C Health Insurance
- C Hospitals & Physicians
- C Pharmaceuticals C Other Health Care
- C Manufacturing
 - Real Estate
 - C Commercial
- C Construction
- C REITS & Finance
- C Residential
- C Other Real Estate

- C Retailing
- C Restaurants
 - Technology
 - C Computers
 - C Telecommunications
 - C Other Technology

Travel

- C Airlines & Airports
- C Lodging & Conventions
- **Tourism & Travel** 0 Services
- C Other Travel
- C Other

First Sale Yet to Occur

5. Issuer Size

Revenue Range

- O No Revenues
- \$1 \$1,000,000
- \$1,000,001 \$5,000,000 0
- 0 \$5,000,001 - \$25,000,000
- \$25,000,001 \$100,000,000 C
- Over \$100.000.000 0
- Decline to Disclose
- O Not Applicable

- Aggregate Net Asset Value Range C No Aggregate Net Asset Value \$1 - \$5,000,000
- \$5,000,001 \$25,000,000 $^{\circ}$
- \$25,000,001 \$50,000,000 C
- \$50,000,001 \$100,000,000 0
- Over \$100.000.000 \sim

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply) Rule 504(b)(1) (not (i), (ii) Γ Rule 505 or (iii))

2009-05-06

Rule 506 Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Securities Act Section 4(6) Rule 504 (b)(1)(iii) Investment Company Act Section 3(c)

Type of Filing

New Notice Date of First Sale

Amendment

- Decline to Disclose C
 - O Not Applicable

B. Duratior	of	Offering	I
-------------------------------	----	----------	---

1							
9. Type(s) of Securitie	es Offered (select all that apply)						
Pooled Investment Fund Interests	Equity						
Tenant-in-Common Securities	Debt						
Mineral Property Securities	Option, Warrant or Other Right to Acquire Another Security						
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security	Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Other (describe)						
10. Business Combin	ation Transaction						
Is this offering being made in co combination transaction, such as exchange offer?	2012 C (2012 C						
Clarification of Response (if Nec	essary)						
11. Minimum Investm	ent						
Minimum investment accepted from any outside investor \$							
12. Sales Compensat	ion						
Recipient	Recipient CRD Number 🔽 None						
(Associated) Broker or Dealer	None (Associated) Broker or Dealer Vone CRD Number						
Street Address 2							
City	State/Province/Country ZIP/Postal Code						

13. Offering and Sales Amounts					
Total Offering Amount	\$ 22000000	USD	Indefinite		
Total Amount Sold	\$ 1000000	USD			
Total Remaining to be Sold	\$ 1200000	USD	Indefinite		
Clarification of Respo	onse (if Necessary)				
14. Investors					

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the offering



Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

15. Sales Commissions & Finders' Fees Expenses

Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

10

Sales Commissions	\$ 0	USD	Estimate
Finders' Fees	\$ 0	USD	Estimate

Clarification of Response (if Necessary)

16. Use of Proceeds

E

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

	\$ 0	USD	Estimate
Clarification of Response (if Necessary)			
I			

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that the Issuer is not disqualified from relying on any Regulation D exemption it
 has identified in Item 6 above for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person. For signature, type in the signer's name or other letters or characters adopted or authorized as

the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Tokai Pharmaceuticals Inc	/s/ Seth L. Harrison	Seth L. Harrison	Chief Executive Officer	2009-05-06